Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Prattichizzo F, de Candia P, Ceriello A. Metabolism 2021 May 21:154799. doi: 10.1016/j.metabol.2021.154799.

Read + Share

Amedeo Smart

Independent Medical Education

Prattichizzo F, de Candia P, Ceriello A. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism 2021 May 21:154799. doi: 10.1016/j.metabol.2021.154799.
PMID: 34029597